Bozen, Sud-Tirol, Italy – November 19th, 2012.
Health Robotics today disclosed its ASHP Mid-Year plans to emphasize its superior solutions for Health-Systems to deal with the recent industry problems due to outsourced sterile compounding company closures, shortages and safety risks, together with its unparalleled advances in Oncology Sterile Compounding at the American Society of Health System Pharmacists (ASHP) Midyear Meeting & Exhibition, to be held in Las Vegas on 2-5 December 2012 (Booth 853).
Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated: “On behalf of the entire Health Robotics’ management team, I invite all ASHP attendees to compare and contrast our company’s track record now yielding streamlined robotic “live” installations within 60 to 90 days from purchase order; new RFID solutions tracking temperature-controlled I.V. doses from the offsite sterile compounding sites to the hospital pharmacies, on to delivery carts and refrigerated cabinets and all the way to the patient; and finally to witness the new standards in Chemotherapy and Monoclonal Antibody Therapy IV Automation.”
Health Robotics will introduce independent and peer-reviewed scientific Oncology Sterile Compounding Automation studies at Health Robotics’ customers such
as Brigham & Women’s Hospital1, and St. Antonius Hospital2, which further increases the clear difference between Health Robotics’ proven 2nd Generation Oncology robotics technology and that of its competitors’3. These Oncology studies show for instance manual versus robotic comparisons in drug potency and patient side effects, $7 per dose direct variable cost savings in consumables, 75% reduction in pharmacist review and approval time, and decreases of 12% to 0.9% in IV errors.
Additionally, since the USA arrival of i.v.STATION ONCO and its adoption by Mercy Hospital in Cedar Rapids and Brigham & Women’s Hospital (as a replacement of CytoCare), interested Health-System pharmacists may schedule private ASHP demos or hospital visits for i.v.STATION ONCO or any other Health
1 Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild, 2012: Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. 2 Peters, Capelle, Arvinte, van de Garde, 2012: Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin® (bevacizumab). Remicade® (infliximab) and Herceptin® (trastuzumab).
3 Robot Competitors: Loccioni-AEA, IHS-RIVA, MDS-Fresenius, FHT-Baxa-Baxter.
Robotics solutions by contacting email@example.com. Health Robotics will also be pleased to showcase at Booth 853 multiple European and American Return on Investment customer studies and testimonials for its world-leading solutions i.v.STATION ONCO and i.v.STATION, as well as to schedule private meetings with Health Robotics’ executive management team, in advance of the meeting.
About Health Robotics:
Founded in 2006, Health Robotics is the undisputed global leading supplier of life- critical intravenous medication robots, winning 100% of all worldwide I.V. Robot’s publicly announced purchases in 2010 and 2011, and providing over 300 hospital installations in 5 continents with robotics-based technology and clinical software automation solutions. Health Robotics’ world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for sterile compounding], OMM® [Oncology Medication Management], MEDarchiver® [life-critical clinical information system], and TPNstation® [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals’ growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics’ products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances’ diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff.
Download in PDF Format :